Cargando…

Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study

Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chalhoub, Issam G., Boulos, Rita T., Dagher, Yara G., El Helou, Sandra, Haifa, Karen G., Atallah, Bachir, Nasr, Fadi, Kassab, Issam, Chahine, Mirna N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545138/
https://www.ncbi.nlm.nih.gov/pubmed/37773843
http://dx.doi.org/10.1097/MD.0000000000034562
_version_ 1785114614754705408
author Chalhoub, Issam G.
Boulos, Rita T.
Dagher, Yara G.
El Helou, Sandra
Haifa, Karen G.
Atallah, Bachir
Nasr, Fadi
Kassab, Issam
Chahine, Mirna N.
author_facet Chalhoub, Issam G.
Boulos, Rita T.
Dagher, Yara G.
El Helou, Sandra
Haifa, Karen G.
Atallah, Bachir
Nasr, Fadi
Kassab, Issam
Chahine, Mirna N.
author_sort Chalhoub, Issam G.
collection PubMed
description Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development and statins intake is controversial, and there are no clear studies in Lebanon and the Middle East concerning this topic. Hence, our study aimed to search for any possible association of statin intake as well as other medications (proton pump inhibitors [PPI], metformin, Aspirin, Angiotensin-Converting Enzyme inhibitors, and fenofibrate) with lung, colorectal cancer (CRC), and bladder cancer development in the Lebanese population. A retrospective study was performed on 709 subjects divided into 2 main groups: control (no cancer ± statin intake), and cases (either lung, or colorectal, or bladder cancer ± statin intake). Collected data included the age and gender of the patient, socioeconomic status, presence of cardiovascular disease and comorbidities, cancer risk factors, and the intake type, dose, and duration of statins. Bivariate, multivariate, and binary logistic analyses were enrolled. Out of 709 participants, 63.2% were males and 75% were cancer-positive (24.1%: lung cancer, 26.7%: CRC, 24.1%: bladder cancer). The overall intake of statins was not shown to significantly affect cancer development. However, a duration-response relationship was established between Simvastatin and lung cancer (odds ratio [OR]=1.208) as well as bladder cancer (OR=1.189). No significant association was found between each statin and CRC. Although PPIs intake was associated with a possibly harmful effect on lung cancer development (OR=3.42), it revealed a protective association with CRC development (OR=0.38). Other risk factors such as smoking and age were strongly associated (harmful) with lung and bladder cancer development. Physical inactivity and a family history of CRC were each associated with a harmful effect on CRC development. A harmful association with the development of lung and bladder cancer was found with the increasing duration of intake of Simvastatin. Other drugs such as PPIs and specific risk factors were also associated negatively or positively with the development of these 3 cancers. These findings should be validated by further investigations to guide clinicians on optimal treatment options for their patients.
format Online
Article
Text
id pubmed-10545138
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-105451382023-10-03 Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study Chalhoub, Issam G. Boulos, Rita T. Dagher, Yara G. El Helou, Sandra Haifa, Karen G. Atallah, Bachir Nasr, Fadi Kassab, Issam Chahine, Mirna N. Medicine (Baltimore) 3400 Elevated blood levels of low-density lipoprotein cholesterol are a major cardiovascular risk factor, and cholesterol-lowering drugs are among the most prescribed drugs worldwide. Cancer is the second leading cause of death after cardiovascular diseases. The relationship between cancer development and statins intake is controversial, and there are no clear studies in Lebanon and the Middle East concerning this topic. Hence, our study aimed to search for any possible association of statin intake as well as other medications (proton pump inhibitors [PPI], metformin, Aspirin, Angiotensin-Converting Enzyme inhibitors, and fenofibrate) with lung, colorectal cancer (CRC), and bladder cancer development in the Lebanese population. A retrospective study was performed on 709 subjects divided into 2 main groups: control (no cancer ± statin intake), and cases (either lung, or colorectal, or bladder cancer ± statin intake). Collected data included the age and gender of the patient, socioeconomic status, presence of cardiovascular disease and comorbidities, cancer risk factors, and the intake type, dose, and duration of statins. Bivariate, multivariate, and binary logistic analyses were enrolled. Out of 709 participants, 63.2% were males and 75% were cancer-positive (24.1%: lung cancer, 26.7%: CRC, 24.1%: bladder cancer). The overall intake of statins was not shown to significantly affect cancer development. However, a duration-response relationship was established between Simvastatin and lung cancer (odds ratio [OR]=1.208) as well as bladder cancer (OR=1.189). No significant association was found between each statin and CRC. Although PPIs intake was associated with a possibly harmful effect on lung cancer development (OR=3.42), it revealed a protective association with CRC development (OR=0.38). Other risk factors such as smoking and age were strongly associated (harmful) with lung and bladder cancer development. Physical inactivity and a family history of CRC were each associated with a harmful effect on CRC development. A harmful association with the development of lung and bladder cancer was found with the increasing duration of intake of Simvastatin. Other drugs such as PPIs and specific risk factors were also associated negatively or positively with the development of these 3 cancers. These findings should be validated by further investigations to guide clinicians on optimal treatment options for their patients. Lippincott Williams & Wilkins 2023-09-29 /pmc/articles/PMC10545138/ /pubmed/37773843 http://dx.doi.org/10.1097/MD.0000000000034562 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 3400
Chalhoub, Issam G.
Boulos, Rita T.
Dagher, Yara G.
El Helou, Sandra
Haifa, Karen G.
Atallah, Bachir
Nasr, Fadi
Kassab, Issam
Chahine, Mirna N.
Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title_full Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title_fullStr Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title_full_unstemmed Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title_short Statins, commonly coprescribed drugs, and concomitant risk factors: A protective, neutral, or harmful association with common cancer types development: A 10-year multicentric retrospective lebanese study
title_sort statins, commonly coprescribed drugs, and concomitant risk factors: a protective, neutral, or harmful association with common cancer types development: a 10-year multicentric retrospective lebanese study
topic 3400
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10545138/
https://www.ncbi.nlm.nih.gov/pubmed/37773843
http://dx.doi.org/10.1097/MD.0000000000034562
work_keys_str_mv AT chalhoubissamg statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT boulosritat statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT dagheryarag statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT elhelousandra statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT haifakareng statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT atallahbachir statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT nasrfadi statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT kassabissam statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy
AT chahinemirnan statinscommonlycoprescribeddrugsandconcomitantriskfactorsaprotectiveneutralorharmfulassociationwithcommoncancertypesdevelopmenta10yearmulticentricretrospectivelebanesestudy